Edgewise Therapeutics Q2 net loss widens on higher expenses

Edgewise Therapeutics

06/08/2026 13:17

Overview
US cardiovascular drug developer's Q2 net loss widened yr/yr on higher R&D and admin expenses
Company completed $2.65 bln sale of muscular dystrophy business to Servier in July 2026

Result Drivers
ORGANIZATIONAL EXPANSION - Co said higher G&A expenses reflected increased personnel costs, stock-based compensation, and professional fees to support clinical development
STRATEGIC FOCUS SHIFT - Sale of muscular dystrophy business to Servier strengthened balance sheet and sharpened focus on cardiovascular pipeline

Company press release: ID:nPn7DbX5ra

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$57.33 mln
 
Q2 Loss Per Basic Share
 
$0.53
 
Q2 Operating Expenses
 
$61.94 mln
 
Q2 Operating Income
 
-$61.94 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Edgewise Therapeutics Inc is $51.50, about 14.5% above its August 5 closing price of $44.99

Reuters Recommended Reads
Aug 5 - Enliven Therapeutics Q2 net loss widens on higher expenses
Aug 5 - United Therapeutics Q2 revenue misses estimates on Ebulized Tyvaso weakness
Aug 6 - Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)